MedTrace Logo

Resveratrol as a Preventive Treatment of OHSS

NCT03446625 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2019-08-20

No results posted yet for this study

Summary

Evaluation of resveratrol treatment oh ovarian hyperstimulation syndrome in egg donors

Conditions

Interventions

DRUG

Resveratrol

Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.

DRUG

Placebo

Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.

Sponsors & Collaborators

  • IVI Madrid

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-13
Primary Completion
2018-10-01
Completion
2019-06-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03446625 on ClinicalTrials.gov